Corolabs

Company Overview

Snapshot

Founded in April 2020 by Asaf Weinberger, Corolabs operates with 1–10 employees. The company holds one patent and is currently in the Pre-Funding stage, focusing on deep-lung inhalation therapies. Corolabs ceased operations in December 2024.

Business overview

Corolabs develops innovative deep-lung inhalation therapies for infectious diseases, utilizing a novel aerosol technology to deliver sub-micron droplets to the alveoli. This technology enables localized treatment of lower respiratory diseases and systemic drug delivery, allowing for home-based treatments traditionally requiring hospital intervention. The company's approach aims for rapid onset of action, dose sparing, and reduced side effects, serving the healthcare and life sciences sectors, particularly pharmaceuticals, providers, and patients.

Company Intelligence Q&A

What is Corolabs' primary focus?

Corolabs focuses on developing deep-lung inhalation therapies for infectious diseases, utilizing a novel delivery system for targeted drug administration.

When was Corolabs founded?

Corolabs was founded in April 2020 by Asaf Weinberger.

What is the status of Corolabs?

Corolabs is currently non-active and ceased to operate in December 2024.

What technology does Corolabs employ?

Corolabs employs an aerosol technology designed to produce and deliver sub-micron droplets to the alveoli of the lung for localized and systemic drug delivery.

Who are the founders of Corolabs?

Asaf Weinberger is a co-founder and CEO of Corolabs.